Bao Sun

1.8k total citations · 1 hit paper
34 papers, 1.3k citations indexed

About

Bao Sun is a scholar working on Molecular Biology, Cancer Research and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Bao Sun has authored 34 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 11 papers in Cancer Research and 10 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Bao Sun's work include Diabetes Treatment and Management (8 papers), Diabetes Management and Research (7 papers) and RNA modifications and cancer (7 papers). Bao Sun is often cited by papers focused on Diabetes Treatment and Management (8 papers), Diabetes Management and Research (7 papers) and RNA modifications and cancer (7 papers). Bao Sun collaborates with scholars based in China. Bao Sun's co-authors include Zheng Zhou, Chunsheng Zhu, Dongsheng Yu, Shiqiong Huang, Zheng Zhou, Meng Bian, Jiecan Zhou, Zhiying Luo, Lingling Zhao and Anzheng Nie and has published in prestigious journals such as Scientific Reports, International Journal of Molecular Sciences and Frontiers in Immunology.

In The Last Decade

Bao Sun

32 papers receiving 1.2k citations

Hit Papers

Gut Microbiota: An Important Player in Type 2 Diabetes Me... 2022 2026 2023 2024 2022 50 100 150 200

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bao Sun China 19 738 393 287 162 130 34 1.3k
Jinghua Liu China 22 733 1.0× 188 0.5× 122 0.4× 160 1.0× 168 1.3× 75 1.5k
Wenjuan Li China 19 403 0.5× 137 0.3× 132 0.5× 143 0.9× 136 1.0× 32 832
Süheda Erener Canada 13 603 0.8× 245 0.6× 160 0.6× 145 0.9× 326 2.5× 16 1.3k
Vincenzo Grimaldi Italy 21 554 0.8× 193 0.5× 113 0.4× 103 0.6× 281 2.2× 68 1.3k
Zehua Zhao China 17 872 1.2× 290 0.7× 167 0.6× 281 1.7× 147 1.1× 48 1.5k
Shigenori Yamamoto Japan 19 699 0.9× 125 0.3× 112 0.4× 101 0.6× 278 2.1× 94 1.3k
Dan Huang China 18 753 1.0× 228 0.6× 54 0.2× 145 0.9× 89 0.7× 56 1.3k
Jerzy Kotlinowski Poland 16 657 0.9× 198 0.5× 64 0.2× 87 0.5× 101 0.8× 39 1.0k
Alexander Sigrüener Germany 15 598 0.8× 149 0.4× 91 0.3× 234 1.4× 161 1.2× 23 999

Countries citing papers authored by Bao Sun

Since Specialization
Citations

This map shows the geographic impact of Bao Sun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bao Sun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bao Sun more than expected).

Fields of papers citing papers by Bao Sun

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bao Sun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bao Sun. The network helps show where Bao Sun may publish in the future.

Co-authorship network of co-authors of Bao Sun

This figure shows the co-authorship network connecting the top 25 collaborators of Bao Sun. A scholar is included among the top collaborators of Bao Sun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bao Sun. Bao Sun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Duan, Xiaohui, Xiaomeng Zhang, & Bao Sun. (2025). The landscape of novel antidiabetic drugs in diabetic HFpEF: relevant mechanisms and clinical implications. Cardiovascular Diabetology. 24(1). 186–186.
2.
Sun, Bao, et al.. (2024). Current landscape and comprehensive management of glycemic variability in diabetic retinopathy. Journal of Translational Medicine. 22(1). 700–700. 5 indexed citations
3.
Zhou, Zheng, et al.. (2024). Anti-hyperuricemia effect of Clerodendranthus spicatus: a molecular biology study combined with metabolomics. Scientific Reports. 14(1). 15449–15449. 5 indexed citations
4.
Liu, Wenhui, Zhiying Luo, Yiping Liu, & Bao Sun. (2023). Current landscape and tailored management of immune-related adverse events. Frontiers in Pharmacology. 14. 1078338–1078338. 4 indexed citations
5.
Yu, Dongsheng, Jiye Li, Yu Wang, et al.. (2023). Oridonin ameliorates doxorubicin induced-cardiotoxicity via the E2F1/Sirt6/PGC1α pathway in mice. Food and Chemical Toxicology. 181. 114050–114050. 6 indexed citations
6.
Luo, Jian‐Quan, Huiqing Chen, Fang Ma, et al.. (2022). Vitamin D metabolism pathway polymorphisms are associated with efficacy and safety in patients under anti-PD-1 inhibitor therapy. Frontiers in Immunology. 13. 937476–937476. 10 indexed citations
7.
Tang, Bingjie, Bao Sun, Lei Chen, et al.. (2022). The Landscape of Exosome-Derived Non-Coding RNA in Leukemia. Frontiers in Pharmacology. 13. 912303–912303. 8 indexed citations
8.
Zhu, Chunsheng, et al.. (2022). Comprehensive elaboration of circular RNA in multiple myeloma. Frontiers in Pharmacology. 13. 971070–971070. 5 indexed citations
9.
Zhou, Zheng, Bao Sun, Dongsheng Yu, & Chunsheng Zhu. (2022). Gut Microbiota: An Important Player in Type 2 Diabetes Mellitus. Frontiers in Cellular and Infection Microbiology. 12. 834485–834485. 209 indexed citations breakdown →
10.
Liu, Wenhui, et al.. (2022). Durvalumab-Induced Demyelinating Lesions in a Patient With Extensive-Stage Small-Cell Lung Cancer: A Case Report. Frontiers in Pharmacology. 12. 799728–799728. 1 indexed citations
11.
Sun, Bao, Zhiying Luo, & Jiecan Zhou. (2021). Comprehensive elaboration of glycemic variability in diabetic macrovascular and microvascular complications. Cardiovascular Diabetology. 20(1). 9–9. 102 indexed citations
12.
Zhang, Xiaochun, Xue Yang, Bao Sun, & Chunsheng Zhu. (2021). Perspectives of glycemic variability in diabetic neuropathy: a comprehensive review. Communications Biology. 4(1). 1366–1366. 29 indexed citations
13.
Zhou, Zheng, Bao Sun, Dongsheng Yu, & Meng Bian. (2021). Roles of tRNA metabolism in aging and lifespan. Cell Death and Disease. 12(6). 548–548. 26 indexed citations
14.
Yin, Yi, Bingjie Tang, Lei Chen, et al.. (2021). CircRNA Microarray Profiling Reveals hsa_circ_0058493 as a Novel Biomarker for Imatinib-Resistant CML. Frontiers in Pharmacology. 12. 728916–728916. 22 indexed citations
15.
Zhou, Zheng, Bao Sun, Shiqiong Huang, Chunsheng Zhu, & Meng Bian. (2020). Glycemic variability: adverse clinical outcomes and how to improve it?. Cardiovascular Diabetology. 19(1). 102–102. 146 indexed citations
16.
He, Fazhong, Bao Sun, Ling Li, et al.. (2020). TRIB3 rs6037475 is a potential biomarker for predicting felodipine drug response in Chinese patients with hypertension. Annals of Translational Medicine. 8(7). 437–437. 7 indexed citations
17.
Zhou, Zheng, Bao Sun, Shiqiong Huang, Dongsheng Yu, & Xiaochuan Zhang. (2020). Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer. Cell Death and Disease. 11(7). 579–579. 45 indexed citations
18.
Zhou, Zheng, Bao Sun, Shiqiong Huang, & Lingling Zhao. (2019). Roles of circular RNAs in immune regulation and autoimmune diseases. Cell Death and Disease. 10(7). 503–503. 155 indexed citations
19.
Nie, Anzheng, Bao Sun, Zhihui Fu, & Dongsheng Yu. (2019). Roles of aminoacyl-tRNA synthetases in immune regulation and immune diseases. Cell Death and Disease. 10(12). 901–901. 73 indexed citations
20.
Zhou, Zheng, Bao Sun, Shiqiong Huang, Wenrui Jia, & Dongsheng Yu. (2019). The tRNA-associated dysregulation in diabetes mellitus. Metabolism. 94. 9–17. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026